Pharmaceutical Drug Development Sector Scorecard, Q2 2022 Update – Thematic Research
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The genomics landscape was active in Q2 2022, with scores increasing for several companies. This includes Merck & Co, whose score increased to 4 due to an increase in forecasted sales for several Phase II candidates, including its oncolytic vaccine Cavatak (gebasaxturev), an mRNA vaccine, and its recombinant vector vaccine V-184 for Chikungunya fever.
In Regenerative Medicine, AstraZeneca saw an increase in its score due to forecasted global sales for its oligonucleotide AZD-8601 and an increase in posted jobs in Q2 2022. AbbVie’s score for nanotechnology was changed to 5 due to an increase in forecasted global sales for its antibody-drug conjugates (ADC) ABBV-154 and telisotuzumab vedotin.
Key themes | Genomics, Nanotechnology, and Rare Disease |
The pharmaceutical drug development sector scorecard report offers in-depth research into a specific theme (such as AI or cybersecurity). The report identifies winners and losers based on technology leadership, market position, and other factors. It also covers all themes within a sector, giving readers a strong sense of how everything fits together and how conflicting themes might interact with one another. Moreover, each sector scorecard identifies the companies that are most likely to succeed in a world filled with disruptive threats.
Pharmaceutical Drug Development – Key Themes
Some of the key themes that have impacted the drug development thematic scorecard in Q2 2022 are as follows:
Genomics
Cadila Pharmaceuticals’s score has been increased from 1 to 3 following the launch of its recombinant vector vaccine for rabies, ThRabis, in April 2022. This is the world’s first three-dose rabies vaccine, with all existing regimens requiring five doses.
Nanotechnology
In June 2022, it was rumored that Merck & Co could acquire Seagen, a leader in the development of ADCs in oncology. If this acquisition is completed, Merck & Co’s score for Nanotechnology would increase to 5.
Rare Disease
GSK’s score for Rare Disease has been increased from 4 to 5 due to the announcement in April 2022 that it was to acquire Sierra Oncology. Sierra Oncology’s momelotinib dihydrochloride is in late-stage development for the treatment of myelofibrosis, thrombocythemia myelofibrosis, and post-polycythemia vera myelofibrosis in the US and Europe.
For more insights on the key themes impacting the drug development thematic scorecard, download a free report sample
Scope
- GlobalData’s Drug Development Scorecard provides a top-down, comprehensive outlook for the key players in the drug development sector over the next two to four years, based on 10 of the major themes set to transform the landscape.
- These 10 themes are Immuno-oncology, Regenerative Medicine, Precision & Personalized Medicine, Rare Disease, Biosimilars, Genomics, Microbiome, Nanotechnology, Strategic Alliances, Artificial Intelligence,
- The scorecard includes 53 companies from across the industry, including biopharmaceutical companies, biosimilar, and generic manufacturers, contract development and manufacturing organizations (CDMOs), and contract research organizations (CROs).
- It is important to note that this scorecard is not an assessment of the current performance of a company in a theme, but a view of future performance based on current levels of activity and investment.
- The methodology section contains information on what data sources were used to generate the thematic scores for each company.
- The scorecard is live on the PIC and will be updated quarterly.
Reasons to Buy
- Identify the key drug development themes for the next 2-4 years and learn how they will impact the market.
- Understand which key themes should be addressed to drive the share price.
- Understand which companies are best positioned for success within critical themes and why.
- Learn which companies have underinvested in key themes and are most vulnerable to disruption.
- Help companies adapt their strategy to anticipate and benefit from these themes as they play out.
- Help identify future winners and losers in drug development to inform partnership strategies.
Merck & Co Inc
AstraZeneca Plc
Bristol-Myers Squibb Co
Pfizer Inc
Johnson & Johnson
Boehringer Ingelheim
Parexel International Corp
F. Hoffmann-La Roche Ltd
Novartis AG
GSK Plc
Bayer AG
Eli Lilly and Co
IQVIA Holdings Inc
AbbVie Inc
Merck KGaA
Novo Nordisk AS
Catalent Inc
Gilead Sciences Inc
Thermo Fisher Scientific Inc
Astellas
Biogen Inc
Cipla Ltd
Lonza Group Ltd
Amgen Inc
Daiichi Sankyo Co Ltd
Vertex Pharmaceuticals Inc
WuXi AppTec Co Ltd
Charles River Laboratories International Inc
CSL Ltd
Reliance Life Sciences Pvt Ltd
Sanofi
Innovent Biologics Inc
Otsuka
Teva Pharmaceutical Industries Ltd
UCB
Dr. Reddy's Laboratories Ltd
Regeneron Pharmaceuticals Inc
Samsung Bioepis Co Ltd
Sun Pharmaceutical Industries Ltd
Biocad
Cadila Pharmaceuticals Ltd
Celltrion Inc
Coherus BioSciences Inc
CSPC Pharmaceutical Group Ltd
Generium
Intas Pharmaceuticals Ltd
Lupin Ltd
Perrigo Co Plc
Seagen Inc
Shanghai Henlius Biotech Inc
Viatris Inc
Zydus Lifesciences
Table of Contents
Frequently asked questions
-
What are the key themes that have impacted the drug development thematic scorecard in Q2 2022?
Some of the key themes that have impacted the drug development thematic scorecard in Q2 2022 are genomics, nanotechnology, and rare disease.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.